Latest Articles
Excess heme orchestrates progesterone resistance in uterine endometrial cancer through macrophage polarization and the IL-33/PAX8/PGR axis - ScienceDirect.com
Excess heme orchestrates progesterone resistance in uterine endometrial cancer through macrophage polarization and the IL-33/PAX8/PGR axis ScienceDirect.com
Published: April 1, 2025, 2:47 p.m.
Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR - Nature
Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR Nature
Published: April 1, 2025, 1:15 p.m.
Dr Lee on Responses With Nivolumab in Resectable dMMR Endometrial Cancer - OncLive
Dr Lee on Responses With Nivolumab in Resectable dMMR Endometrial Cancer OncLive
Published: March 31, 2025, 10:21 p.m.
CD8+ T Cell Activation in Endometrial Cancer: Prognostic Implications and Potential for - Frontiers
CD8+ T Cell Activation in Endometrial Cancer: Prognostic Implications and Potential for Frontiers
Published: March 31, 2025, 7:23 p.m.
Optimizing Management Strategies for Advanced Endometrial Cancer Progression After IO-Chemo - OncLive
Optimizing Management Strategies for Advanced Endometrial Cancer Progression After IO-Chemo OncLive
Published: March 31, 2025, 2:14 p.m.
Overview of Current Treatment Landscape of Advanced Endometrial Cancer - OncLive
Overview of Current Treatment Landscape of Advanced Endometrial Cancer OncLive
Published: March 31, 2025, 2:03 p.m.
(PDF) Robotic single site versus robotic multiport hysterectomy in endometrial cancer: a systematic review and meta-analysis - ResearchGate
(PDF) Robotic single site versus robotic multiport hysterectomy in endometrial cancer: a systematic review and meta-analysis ResearchGate
Published: March 31, 2025, 4:02 a.m.
Expression of NUMB Protein and Its Prognostic Significance in Endometrial Cancer: A Retrospective Cohort Study - Cureus
Expression of NUMB Protein and Its Prognostic Significance in Endometrial Cancer: A Retrospective Cohort Study Cureus
Published: March 29, 2025, 8:01 a.m.
Dr Lan on the Efficacy of Cadonilimab Plus Lenvatinib in Advanced Endometrial Cancer - OncLive
Dr Lan on the Efficacy of Cadonilimab Plus Lenvatinib in Advanced Endometrial Cancer OncLive
Published: March 28, 2025, 10:08 p.m.
Breakthrough: Acrivon's Cancer Drug Shows 35% Response Rate in Hard-to-Treat Endometrial Cancer - StockTitan
Breakthrough: Acrivon's Cancer Drug Shows 35% Response Rate in Hard-to-Treat Endometrial Cancer StockTitan
Published: March 27, 2025, 9:44 p.m.
Link copied to clipboard!